October 2021 OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
October 2021 OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’